Corcept Therapeutics Publishes MOMENTUM Study Results on Hypertension and Cortisol Levels
The biopharmaceutical company released research characterizing individuals with resistant hypertension across different post-dexamethasone cortisol thresholds.
MOMENTUM Study Findings Released
Corcept Therapeutics Incorporated (NASDAQ: CORT) announced the publication of research results from its MOMENTUM study on July 30, examining individuals with resistant hypertension and varying levels of post-dexamethasone suppression test cortisol. The study, authored by Eilerman et al. and published in ENDO in 2026, characterized patients across three cortisol threshold groups: less than 1.2 μg/dL, between 1.2–1.8 μg/dL, and greater than 1.8 μg/dL.
The research represents a continued focus on understanding the relationship between cortisol dysregulation and resistant hypertension, an area central to Corcept's therapeutic development strategy. The company, which specializes in cortisol modulation therapies, has built its $13 billion market capitalization on treatments targeting conditions involving excess cortisol activity.
Clinical Significance
The dexamethasone suppression test is a diagnostic tool used to assess cortisol regulation in patients. By stratifying resistant hypertension patients according to their cortisol suppression responses, the MOMENTUM study provides data that could inform clinical decision-making and patient identification strategies for cortisol-related interventions.
Resistant hypertension affects patients whose blood pressure remains elevated despite treatment with multiple antihypertensive medications, representing a significant unmet medical need.
Recent Corporate Activity
According to MarginX data, recent insider activity shows Atabak Mokari exercising options for 24,167 shares and 15,833 shares in separate transactions, followed by a sale of 28,460 shares. Corcept's stock closed at $118.32 in its most recent session.
Looking Ahead
Corcept is expected to report third-quarter 2026 results on November 4, 2026, according to MarginX data. Investors will be monitoring the company's commercial performance and pipeline progress as it continues to develop its portfolio of cortisol modulation therapies. The Federal Reserve is scheduled to make rate decisions with projections on September 16 and again on October 28.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.